

Fenofibrate Characterization of Solid Lipid Nanoparticles Using the High Shear Homogenization Method

by Ilham Kuncahyo

Submission date: 19-Feb-2023 02:00AM (UTC+0700)

Submission ID: 2017342023

File name: Artikel_2022_M_Khoiriyah.pdf (346.54K)

Word count: 3273

Character count: 16861



Natural Sciences Engineering & Technology Journal (NASET Journal)

Journal Homepage: <https://nasetjournal.com/index.php/nasetjournal>

19

Fenofibrate Characterization of Solid Lipid Nanoparticles Using the High Shear Homogenization Method

Muhimmatul Khoiriyah^{1*}, Jason Merari Perangirangin¹, Ilham Kuncahyo¹

¹ Department of Pharmacy Sciences, Faculty of Pharmacy, Universitas Setia Budi Surakarta, Surakarta, Indonesia

ARTICLE INFO

Keywords:

Fenofibrate
Solid lipid nanoparticles
High shear homogenization

Corresponding author:

Muhimmatul Khoiriyah

E-mail address:

muhimmatul67@gmail.com

All authors have reviewed and approved the final version of the manuscript.

1
<https://doi.org/10.37275/NASETJournal.v2i2.21>

ABSTRACT

Fenofibrate is a drug that can be used to treat hyperlipidemia where the drug is included in the category of Biopharmaceutical classification system II with poor solubility and high permeability. This causes the need to improve the drug delivery system (DDS) made using the Solid Lipid Nanoparticle (SLN) method. SLN fenofibrate can be made using the High Shear Homogenization method by determining the formula using Factorial 22 Design Expert 12, the formula is made with a concentration of 0.31-1.25% GMS and 1.25-2% Tween-40, then SLN fenofibrate is made by mixing all ingredients until an emulsion is formed and continued with the SLN critical parameter test. From the test results, the critical parameters of SLN fenofibrate for the particle size of 8 formulas 490; 561; 601; 697; 916; 1040; 1818, and 2410 nm. The results obtained for the polydispersity index respectively were 0.02; 0.04; 0.08; 0.30; 0.35; 0.48; 0.51, and 0.65. The zeta potential value of the 8 formulas obtained successive values of 2.8; 3.5; 4.2; 4.8; 5.5; 5.8; 8.1 and 8.8 mV. Calculation of the efficiency of the SLN fenofibrate drug obtained successive values of 77.23; 78.53; 79.51; 80.47; 81.17; 87.38; 87.39 and 87.82%. The SLN method can improve drugs that are included in the Biopharmaceutical classification system class II category with the distribution of test results in the particle size range and the adsorbed drug is more than 70%.

1. Introduction

23
Fenofibrate is a fibrate hypolipidemic drug, a peroxisome proliferator-activated receptor α (PPAR α) agonist that can downregulate the apoC-III gene and upregulate the apoA-1 and apoA-genes. II, to reduce serum triglyceride levels. Fenofibrate is insoluble in water with a solubility level of 162.5 g/mL. Based on the biopharmaceutical classification system (BCS), fenofibrate is included in the BCS class II category where drugs that fall into this category have poor solubility and high permeability. (Low solubility and permeability drugs). A poorly soluble drug has a low dissolution rate in liquid digestion, thus causing poor bioavailability in the body.^{1,2}

Drugs that have poor solubility can be improved

by using a drug delivery system (DDS) such as reducing particle size, decreasing crystallinity, making particles amorphous, and increasing drug particle limitations. Solid Lipid Nanoparticles (SLN) can increase drug stability and can provide flexibility in controlling the release of drug substances and can provide an occlusive effect that can increase the penetration of active ingredients. The method that can be used to make SLN preparations is using ultrasonication or high-speed homogenization methods where the active ingredient is dissolved into solid oil with the addition of a surfactant after the formation of an emulsion, then sonication is carried out.³ A study showed that fenofibrate nano

preparations were able to increase the solubility and dissolution rate of the drug.⁴

SLN fenofibrate was made by the High Shear Homogenization method using solid lipids of the glyceride group. The advantage of the lipid group of glycerides is that it can provide an increase in the manufacture of stable drugs. With a combination of surfactant tween 40 is used as a stabilizer and added singly with a concentration of 1.33–2% is expected to increase stability and reduce particle size.^{5,6} This study aims to determine the effect of the combination of Glycerin Monostearate and Tween 40 on the characteristics of fenofibrate Solid Lipid Nanoparticles made by the High Shear Homogenization method.

2. Methods

The materials used in this study were fenofibrate, glyceryl monostearate, Tween 40, and aqua dest. The tools used in this research are analytical balance (Precisa & B 220A), Hot Plate Magnetic Stirrer (Thermo Scientific), Ultrasonicator, Particle Size Analyzer (Microtrac Nanotrac Wave II), Polydispersion index (Microtrac Nanotrac Wave II), Zeta potential (Microtrac Nanotrac Wave II), Centrifuge, UV-Vis Spectrophotometer, and beaker. Fenofibrate Solid Lipid Nanoparticle (SLN) formulation by determining the concentration of the formula using Design Expert from solid fats and surfactants where each concentration has 2 levels, namely low level (GMS 0.31% and Tween 40 1.33%) and high level (GMS 1,25% and Tween 40 2%).

Table 1. Design factors and concentrations of 2³ factorial design

Formula	Fenofibrate (% w/w)	GMS (% w/w)	Tween 40 (% w/w)	Water (% w/w)
Run 1	0.12	1.25	1.33	97,3
Run 2	0.12	1.25	2	96,63
Run 3	0.12	0.31	2	97,57
Run 4	0.12	1.25	1.33	97,3
Run 5	0.12	0,31	2	97,57
Run 6	0.12	1.25	2	96,63
Run 7	0.12	0.31	1.33	98,24
Run 8	0.12	0.31	1.33	98,24

SLN fenofibrate was prepared with GMS and Tween 40 with various ratios (Table 2) dissolved in water. GMS dissolved with some water, stirred using a Hot Plate Magnetic Stirrer at a speed of 700 rpm at a temperature of 80°C for 15 minutes, after 15 minutes fenofibrate was added until dissolved. Tween 40 was dissolved with some water, stirred at a speed of 700 rpm using a Hot Plate Magnetic Stirrer for 15 minutes at a temperature of 80°C, then put the Tween 40 solution into the GMS-Fenofibrate solution, stirred with a Hot Plate Magnetic Stirrer at a

speed of 700 rpm to form an emulsion. The fenofibrate emulsion preparation was then ultrasonicated for 15 minutes by pulse on-off method for 10 seconds with an amplitude of 55% the formulation was left to room temperature. The formulations were tested for particle size, polydispersity index, zeta potential (using Microtrac Wave II), and adsorption efficiency.

Determination of the wavelength was carried out by making a mother liquor, carefully weighed 10.0 mg of fenofibrate dissolved in a 100.0 ml volumetric flask, so

that a concentration of 100 ppm was obtained. The mother liquor was taken at 1.0 ml which was dissolved using ethanol solvent into a measuring flask to 10.0 ml so that a concentration of 10 ppm was obtained. Read with a UV-Vis spectrophotometer with a wavelength between 200-400 nm. The maximum wavelength is indicated by the highest absorption value.

The characterization of SLN fenofibrate can be done by testing the particle size, polydispersity index and zeta potential using the Microtrac Nanotracs Wave II tool with

an RI setting of 3.33 where the sample to be tested should not be bubbly and foamy, the sample is inserted into the cap, then determine the run and results. the reading will be read on the system connected to the computer. efficiency test adsorption was carried out with SLN fenofibrate centrifuged at 6000 rpm for 60 minutes, the supernatant (non-absorbed drug) was measured using a UV-Vis spectrophotometer with a maximum wavelength, the absorbance value obtained was calculated by the formula:

$$\text{Adsorption efficiency (\%)} = \frac{W_a - W_s}{W_a} \times 100\%$$

Information:

W_a: The mass of the drug added to the formula

W_s: Analysis of the weight of the drug in the supernatant

3. Results and Discussion

Determination of wavelength

The results of screening of pure fenofibrate standard solution were carried out with a concentration of 2 ppm

at a wavelength of 200 -400 nm using a UV-Vis spectrophotometer. From the results of the analysis, the wavelength of fenofibrate is 286 nm with an absorption magnitude of 0.5720.




Figure 1. Maximum wavelength.

Characterization test of SLN fenofibrate

SLN fenofibrate characterization test was carried out, including particle size, polydispersion index, zeta potential, which could be measured using a Nanotracs

Wave II device with an RI setting of 3.33, and the adsorption could be carried out using a UV-Vis spectrophotometer. The results of the analysis are as follows:

Table 2. SLN fenofibrate characterization test results

Run	PSA	PDI	Zeta	EE
1	916	0.04	2.8	79.51
2	561	0.0842	4.2	78.53
3	1040	0.652	8.8	87.39
4	1818	0.515	5.5	87.82
5	490	0.486	8.1	81.17
6	2410	0.35	4.8	87.39
7	601	0.01858	3.5	77.23
8	697	0.308	5.8	80.47

4 Particle size and polydispersity index

Particle size is the most important parameter in the manufacture of SLN preparations. The use of lipids with the heating method makes the viscosity decrease so that it affects the particle size, the fenofibrate trapped in the GMS causes the SLN size to get smaller.^{7,8} Formula making using GMS makes the preparations have unstable particle sizes because GMS can form crystals of orderliness which makes the drug enter quickly and also easily come out,^{9,10} with the addition of surfactants it is expected to stabilize the emulsion of the two liquids that do not mix so that can reduce the repulsion and intermolecular attractive forces of each liquid and can increase the formation of particle size.^{11,12}

The influence of GMS and Tween 40 with the SLN preparation method can make almost all formulas fall into the nanoparticle size range of 0-1000 nm, the non-uniformity of particle size is caused by the lack of

accuracy when making the formula or when preparing measurements, the non-uniformity of particle size can also be seen from the non-uniformity. The higher the polydispersity index uniformity, it indicates that the resulting particle size is increasingly not same.

With the P-Value Analysis of variance (ANOVA) on Design Expert 12 software with a 95% confidence level (P-Value <0.05), the particle size test and polydispersity index were obtained with values of 0.0201 and 0.0473 where these values <0.05 so the data obtained is significant. Meanwhile, for statistical analysis data, to fulfill the requirements, it must obtain an R2 value close to 1 for the particle size analysis data itself, the R2 value is 0.8946 and the polydispersity index is 0.8365 so that the data meets the requirements, with Adjusted R2 0.8156 for particle size and 0.7138 where the value is above 0.7 which means that the data we get is following the requirements. With the equation value

$$Y = -280.88(A) -372.88 (B) +393.63 (AB) \rightarrow \text{particle size}$$

$$Y= +0.174545(A) -0.561984(B) -0.022055 (AB) \rightarrow \text{polydispersity index}$$

Information: A: GMS, B: Tween 40

From the above equation, it shows that there is an effect between GMS (A) and Tween 40 (B) in each factor and there is an interaction between SLN preparations. The results of the resulting regression coefficients indicate that GMS and tween 40 with negative results affect the particle size test, while in the Polydispersity

index equation the GMS value is positive, which shows that GMS has the greatest influence compared to tween 40. Based on the equation, it can be seen based on the contour plot particle size and polydispersity index are presented in the figure below:

Factor Coding: Actual

PSA

● Design Points

561  5540

X1 = A: GMS

X2 = B: Tween




Figure 2. PSA formulation graph

Factor Coding: Actual

PDI

● Design Points

0.01858  0.652

X1 = A: GMS

X2 = B: Tween




Figure 3. Formulation PDI graph

From the figure above, it can be explained that there is a movement in the counterplot of GMS concentration 0.31-1.25% and tween 40 1.25 -2% which is indicated by the movement of color changes, where orange, yellow and green are the highest concentrations and blue is the lowest concentration that affects the polydispersity index. The results indicate that there is an interaction between the components of the Polydispersion index one another, this is indicated by the presence of color gradations on the contour plot.

Zeta potential

Based on the results of the zeta potential test above

$$Y = +0.9375(A) - 1.36(B) - 0.7125(AB)$$

Information: A: GMS, B: Tween

From the above equation, it can be concluded that there is an interaction between the components of GMS and tween 40 where each of these components can affect the potential Zeta test results. The regression coefficient

+/- 30 mV has shown stability, whereas a surface charge prevents particle aggregation. From the potential results obtained, it shows that the results are quite stable with a negative particle charge which is influenced by the particles dispersed in water because they tend to adsorb hydroxyl ions, besides that it can also be influenced by anionic surfactants.¹³

With the P-Value Analysis of variance (ANOVA) on Design Expert 12 software with a 95% confidence level (P-Value <0.05), the polydispersity index test was 0.0498nm with an R-value of^{0.8321} and Adjusted R2 of 0.7062 where the value meets the requirements. With the equation value

shows a negative result, it shows that the addition of surfactant will affect the low zeta potential value, which can be seen from the figure below.




Figure 4. Graph of Zeta Potential Formulation

From the counterplot figure above, it shows that there is a movement in the contours of both GMS concentrations of 0.31-1.25% and tween 40 of 1.25-2%, where the highest concentrations are shown in orange, yellow, and yellow. green and blue are the lowest concentrations that can affect the zeta potential test. The results indicate that there is an interaction between the adsorption efficiency components with each other, this is indicated by the color gradation on the contour plot.

Adsorption efficiency

The adsorption efficiency is carried out by using a UV-Vis spectrophotometer to determine the percentage of the active substance that is adsorbed in the SLN system, the larger the compound trapped in the carrier, the faster the penetration, because the greater the concentration

gradient that drives the passive diffusion process in penetration. Formula 8 has a higher adsorption efficiency value than the other 7 formulas, this can be influenced by several factors such as the solubility of the drug in melted fat, where the lower the concentration of a lipid used will affect the ability to load drug compounds will be smaller.¹⁴⁻²⁰

With the P-Value Analysis of variance (ANOVA) on Design Expert 12 software with a 95% confidence level (P-Value > 0.05), 52 0.039 and the data is significant. Meanwhile, for statistical analysis data, to meet the requirements, it must obtain an R2 value of more than 0.7 or 70%, for data analysis, the sorption efficiency itself has an R2 value of 0.8457 so that the data meets the requirements, with Adjusted R2 0.7300, with the equation.

$$Y = -15,01477 (A) -17,19014 (B) +8,62972 (AB)$$

Information: A: GMS, B: Tween 40




Figure 5. Graph of formulation adsorption efficiency

The counterplot above with a GMS concentration of 0.31 -1.25% and tween 40 1.25-2% showed a movement of color change from red, yellow, green which was the

highest concentration, and blue was the lowest concentration that could affect the results of the adsorption efficiency test.

4. Conclusion

The SLN method can improve drugs that are included in the Biopharmaceutical classification system class II category with the distribution of test results in the particle size range and the adsorbed drug is more than 70%.

5. References

1. Bagde, A. Formulation of topical ibuprofen solid lipid nanoparticle (SLN) gel using hot melt extrusion technique (HME) and determining its anti-inflammatory strength. *Drug Delivery and Translational Research*. 2019; 9(4): 816–827. doi:10.1007/s13346-019-00632-3.
2. Borkar, N. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in a biorelevant medium. *European Journal of Pharmaceutical Sciences*. 2014; 51(1): 204–210. doi:10.1016/j.ejps.2013.09.022.
3. Ekambaram, P. and Abdul Hasan Sathali, A. Formulation and evaluation of solid lipid nanoparticles of ramipril. *Journal of Young Pharmacists*. 2011; 3(3): 216–220. doi: 10.4103/0975-1483,83765.
4. Freitas, C. and Müller, RH Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles. *International Journal of Pharmaceutics*. 2001; 168(2): 221–229. doi:10.1016/S0378-5173(98)00092-1.
5. Garcês, A. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review. *European Journal of Pharmaceutical Sciences*. 2018; 112: 159–167. doi:10.1016/j.ejps.2017.11.023.
6. Hanafy, A. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. *Advanced Drug Delivery Reviews*. 2017; 59(6): 419–426. doi: 10.1016/j.addr.2007.04.005.
7. Hey, J. Carvacrol loaded solid lipid nanoparticles of propylene glycol monopalmitate and glyceryl monostearate: Preparation, characterization, and synergistic antimicrobial activity. *Nanomaterials*. 2019; 9(8): 1–14. doi:10.3390/nano9081162.
8. Khalil, RM Solid lipid nanoparticles for topical delivery of Meloxicam: development and In Vitro characterization. *European Scientific Journal*. 2014; 4(7): 24–26. Available at: <http://dx.doi.org/10.4172/0975-0851.S1.007>.
9. Khare, A. Design and Evaluation of Voriconazole Loaded Solid Lipid Nanoparticles for Ophthalmic Application. *Journal of Drug Delivery*. 2016; 1–11. doi: 10.1155/2016/6590361.
10. Khurana, S., Jain, NK and Bedi, PMS Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam. *Life Sciences*. 2013; 93(21): 763–772. doi:10.1016/j.lfs.2013.09.027.
11. Kumar, R. Preparation, characterization and in vitro cytotoxicity of Fenofibrate and Nabumetone loaded solid lipid nanoparticles. *Materials Science and Engineering*. 2020; 106: 110184. doi:10.1016/j.msec.2019.110184.
12. Leuner, C. and Dressman, J. Improving drug solubility for oral delivery using solid dispersions. *European Journal of Pharmaceutics and Biopharmaceutics*. 2010; 50(1): 47–60. doi:10.1016/S0939-6411(00)00076-X.
13. Mehnert, W. and Mäder, K. Solid lipid nanoparticles: Production, characterization and applications. *Advanced Drug Delivery Reviews*. 2014; 64(SUPPL.): 83–101. doi:10.1016/j.addr.2012.09.021.
14. Melzig, S. Fluid mechanics and process design of glycerol-pressure antisolvent precipitation of fenofibrate nanoparticles using a customized microsystem. *Chemical Engineering Journal*. 2019; 371: 554–564. doi: 10.1016/j.cej.2019.04.051.
15. Pignatello, R. A method for efficient loading of

- ciprofloxacin hydrochloride in cationic solid lipid nanoparticles: Formulation and microbiological evaluation. *Nanomaterials*.2018; 8(5): 1–11. doi:10.3390/nano8050304.
16. Qushawy, M. and Nasr, A. Solid lipid nanoparticles (SLNs) as nano drug delivery carriers: Preparation, characterization and application. *International Journal of Applied Pharmaceutics*. 2020; 12(1): 1–9. doi: 10.22159/ijap.2020v12i1.35312.
 17. Sastri, KT Solid lipid nanoparticles: Preparation techniques, their characterization, and an update on recent studies. *Journal of Applied Pharmaceutical Science*. 2020; 10(6): 126–141. doi: 10.7324/JAPS.2020.10617.
 18. Shahraeini, SS Atorvastatin Solid Lipid Nanoparticles as a Promising Approach for Dermal Delivery and an Anti-inflammatory Agent. *AAPS PharmSciTech*. 2020; 21(7): 1–10. doi:10.1208/s12249-020-01807-9.
 19. Singh, S. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability. *BioMed Research International*. 2013. doi:10.1155/2013/584549.
 20. Subedi, RK, Kang, KW and Choi, HK Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. *European Journal of Pharmaceutical Sciences*. 2009; 37(3–4): 508–513. doi: 10.1016/j.ejps.2009.04.008.

Fenofibrate Characterization of Solid Lipid Nanoparticles Using the High Shear Homogenization Method

ORIGINALITY REPORT

11%

SIMILARITY INDEX

8%

INTERNET SOURCES

6%

PUBLICATIONS

1%

STUDENT PAPERS

PRIMARY SOURCES

1	nasetjournal.com Internet Source	1%
2	heanoti.com Internet Source	1%
3	www.researchgate.net Internet Source	1%
4	storage.googleapis.com Internet Source	1%
5	www.tandfonline.com Internet Source	1%
6	E. Lugscheider, M. Knepper, A. Nyland. "Characterization of thermal sprayed bioactive coatings", Colloids and Surfaces B: Biointerfaces, 1996 Publication	1%
7	www.dovepress.com Internet Source	1%
8	www.ncbi.nlm.nih.gov Internet Source	

<1 %

9

Noha Badawi, Khalid El-Say, Dalia Attia, Mohamed El-Nabarawi, Mohey Elmazar, Mahmoud Teaima. "Development of Pomegranate Extract-Loaded Solid Lipid Nanoparticles: Quality by Design Approach to Screen the Variables Affecting the Quality Attributes and Characterization", ACS Omega, 2020

Publication

<1 %

10

www.eurjchem.com

Internet Source

<1 %

11

Ankit Javia, Late Ambikanandan Misra, Hetal Thakkar. "Design and pharmacodynamic evaluation of DPK-060 loaded Nanostructured lipid carrier embedded gel for dermal delivery: A novel Approach in the treatment of atopic dermatitis", Colloids and Surfaces B: Biointerfaces, 2022

Publication

<1 %

12

Areen Ashkar, Alejandro Sosnik, Maya Davidovich-Pinhas. "Structured edible lipid-based particle systems for oral drug-delivery", Biotechnology Advances, 2021

Publication

<1 %

13

Hamid Reza Kelidari, Mohammad Djaefar Moemenbellah-Fard, Katayon Morteza-Semnani, Fatemeh Amoozegar et al. "Solid-lipid nanoparticles (SLN)s containing Zataria multiflora essential oil with no-cytotoxicity and potent repellent activity against Anopheles stephensi", Journal of Parasitic Diseases, 2020

Publication

<1 %

14

Madhulika Pradhan, Deependra Singh, Manju Rawat Singh. "Influence of selected variables on fabrication of Triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders", Artificial Cells, Nanomedicine, and Biotechnology, 2014

Publication

<1 %

15

S. Melzig, J.H. Finke, C. Schilde, A. Vierheller, A. Dietzel, A. Kwade. "Fluid mechanics and process design of high-pressure antisolvent precipitation of fenofibrate nanoparticles using a customized microsystem", Chemical Engineering Journal, 2019

Publication

<1 %

16

fount.aucegypt.edu

Internet Source

<1 %

17

innovareacademics.in

Internet Source

<1 %

18 journalamb.com <1 %
Internet Source

19 link.springer.com <1 %
Internet Source

20 macau.uni-kiel.de <1 %
Internet Source

21 www.doria.fi <1 %
Internet Source

22 Ji-Hyun Kang, Jinmann Chon, Young-Il Kim,
Hyo-Jung Lee et al. " <1 %

Preparation and evaluation of tacrolimus-
loaded thermosensitive solid lipid
nanoparticles for improved dermal
distribution

", International Journal of Nanomedicine, 2019
Publication

23 Kaiyue Du, Xin Huang, Ankang Peng, Qinghua
Yang, Du Chen, Jianxiang Zhang, Rong Qi. <1 %
"Engineered Fenofibrate as Oxidation-
Sensitive Nanoparticles with ROS Scavenging
and PPAR α -Activating Bioactivity to
Ameliorate Nonalcoholic Fatty Liver Disease",
Molecular Pharmaceutics, 2022
Publication

Exclude quotes On

Exclude matches Off

Exclude bibliography On